Zim Laboratories Limited
Mathew Cyriac increased his stake in Zim Laboratories from 11.84% to 19.34%, acquiring 40,12,702 shares for ₹26.69 Cr at ₹66.51 apiece through an open market purchase. This transaction crossed the 5% disclosure threshold.
A pharmaceutical manufacturer established in 1989, Zim Laboratories specializes in producing formulation drugs and pre-formulation ingredients for both domestic and international markets. The company operates manufacturing facilities across India with capabilities in drug development, quality assurance, and distribution. It serves healthcare providers and patients through a diversified portfolio of therapeutic formulations marketed within India and exported to markets worldwide.
Led Blackstone India's private equity business and transformed companies like Gokaldas Exports and MTAR Technologies into industry champions. IIM Bangalore gold medallist. Founded Florintree Advisors to continue backing pre-IPO growth platforms, Data Patterns, IdeaForge. His listed equity bets reflect the same PE discipline: a 19%+ stake in ZIM Laboratories, ~3% in Reliance Infra. Concentrated, long-duration, with an operator's eye for what actually creates value.